The field of glaucoma is in a period of rapid innovation, with various novel medical and surgical treatments having been introduced in recent years. From microinvasive glaucoma surgeries to subconjunctival microshunts and new drug delivery devices, the treatment options for glaucoma that are available to the ophthalmologist have increased considerably, and this trajectory will likely continue in the near term.1 Although data are needed from rigorous trials that evaluate and compare these emerging treatments, the question remains, how do we assess the value of treatments for this complex and chronic condition?